RecruitingPhase 2NCT07335601
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate MGL-3196 (Resmetirom) in Patients With MASH Who Have Undergone Liver Transplant for MASH Cirrhosis or Other Etiologies
Sponsor
Madrigal Pharmaceuticals, Inc.
Enrollment
120 participants
Start Date
Dec 29, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH. Cohort 2 will consist of subjects who have undergone liver transplant for indications other than MASH cirrhosis who developed de novo MASH.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria10
- At least 12 months post-liver transplant at screening and meeting one of the following:
- Cohort 1: Liver transplant for MASH cirrhosis with recurrent hepatic steatosis ≥8% by MRI-PDFF
- Cohort 2: Liver transplant for non-MASH etiology with de novo hepatic steatosis ≥8% by MRI-PDFF
- Presence of at least one metabolic risk factor, including overweight/obesity, dysglycemia or type 2 diabetes, hypertension or antihypertensive treatment, hypertriglyceridemia or low HDL cholesterol, or lipid-lowering therapy.
- MASH with moderate to advanced liver fibrosis (F2-F3), confirmed by noninvasive fibrosis assessment (FibroScan and/or MRE) and a liver biopsy consistent with Stage F2/F3 MASH and no evidence of other liver pathology or graft rejection.
- Stable renal function with estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m² prior to and during screening.
- Stable liver enzymes at screening, without clinically significant worsening compared with recent historical values.
- Stable immunosuppressive regimen for at least 4 weeks prior to screening.
- Females of childbearing potential must have a negative pregnancy test, not be breastfeeding, and agree to use effective contraception during the study and for 30 days after the last dose; females not of childbearing potential are eligible.
- Sexually active males with partners of childbearing potential must agree to use effective contraception during the study and for 30 days after the last dose and not donate sperm during this period.
Exclusion Criteria21
- Participation in another interventional clinical trial with investigational drug exposure within 30 days (or 5 half-lives, whichever is longer) prior to screening.
- Phosphatidylethanol (PEth) value of ≥20 ng/mL measured at screening or clinically significant alcohol use within 1 year prior to screening.
- FibroScan VCTE >20 kPa, a baseline biopsy demonstrating fibrosis consistent with F4, or MRE > 5 kPa.
- Uncontrolled or clinically significant thyroid disease, including active hyperthyroidism or untreated hypothyroidism.
- Evidence of active liver disease other than MASH.
- History of liver transplantation for an inborn error of metabolism.
- Evidence of hepatic impairment or decompensation at screening.
- Steroid resistant rejection of the transplanted liver or kidney, or a history of a rejection treated with high dose steroid within 3 months of screening.
- Chronic rejection or chronic plasma-cell hepatitis.
- Significant post-transplant vascular or biliary complications.
- Significant cardiovascular or cerebrovascular disease within 6 months prior to randomization.
- Uncontrolled hypertension at screening or randomization.
- Current hepatocellular carcinoma.
- Known human immunodeficiency virus (HIV) infection or other clinically significant immunocompromised state.
- Any serious medical condition with a life expectancy of less than 5 years.
- Current substance abuse or drug addiction.
- Significant psychiatric, cognitive, or social conditions that would interfere with study participation or compliance, in the Investigator's judgment.
- Known hypersensitivity to study drug or any of its excipients.
- Use of prohibited concomitant medications that may affect liver function, steatosis, thyroid function, or study outcomes, or unstable doses of allowed metabolic therapies prior to randomization.
- Use of statins above protocol-allowed doses or unstable lipid-lowering therapy prior to randomization.
- Contraindications to MRI, including implanted devices incompatible with MRI, severe claustrophobia, or inability to undergo MRI procedures.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGResmetirom
Randomized 80 or 100 mg
DRUGPlacebo
Placebo
Locations(15)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07335601
Related Trials
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314318 locations
Rezdiffra Pregnancy and Lactation Registry
NCT075414691 location
Study of TGM-312-SC01 in Healthy Participants and Adults With MASH
NCT074276801 location
A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT0749145833 locations
High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps
NCT074632871 location